Cost –effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer

Immunotherapy, Ahead of Print.

Source: Immunotherapy - July 7, 2022 Category: Allergy & Immunology Authors: Min Huang Peter Fasching Amin Haiderali Wilbur Pan Emma Gray Zheng-Yi Zhou Peter Hu Mitashri Chaudhuri Celine Le Bailly De Tilleghem Nicolas Cappoen Joyce O ’Shaughnessy Source Type: research